financetom
Business
financetom
/
Business
/
What's Going On With Paramount Global Stock Following Reported Talks Of Skydance Merger?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Paramount Global Stock Following Reported Talks Of Skydance Merger?
Apr 4, 2024 6:05 AM

Paramount Global ( PARAA ) , which turned down a $26 billion bid from Apollo Global Management, Inc. ( APO ) , is now in exclusive discussions with Skydance, the studio behind Top Gun: Maverick.

David Ellison, leading Skydance, has a 30-day window to negotiate a deal with the entity overseen by Shari Redstone’s National Amusements (NAI), a privately held cinema group owning 77% of Paramount’s voting shares, Financial Times reported.

According to Benzinga Pro, PARA stock has lost over 35% in the past year. Investors can gain exposure to the stock via Invesco S&P 500 Equal Weight Communication Services ETF and Invesco S&P 500 Pure Value ETF ( RPV ) 

The proposed arrangement entails Skydance initially acquiring NAI, followed by a subsequent merger with Paramount, the report read, citing people who briefed about the matter.

Ellison and Redstone, both from prominent American families, have been in negotiations for months to finalize a merger between Paramount and Skydance.

The choice to engage in exclusive discussions underscores the mutual intent of both parties to conclude negotiations, the report added. 

This follows Paramount’s board rejecting Apollo’s bid to acquire 100% of the media group’s shareholders at a valuation ranging between $17 and $19.50 per share.

Apollo’s $26 billion takeover bid encompassed debt as part of its valuation, the report added.

Price Action: PARA shares are trading lower by 1.92% to $13.26 premarket on the last check Thursday. 

Image by viewimage via Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
After two-year wait, Danone gears up for Olympics health-kick ahead of Paris Games
After two-year wait, Danone gears up for Olympics health-kick ahead of Paris Games
Apr 18, 2024
LONDON, April 18 (Reuters) - Danone, whose CEO first reached out to the International Olympic Committee (IOC) in mid-2022 to get involved, is betting on the Paris Games' focus on health and nutrition to boost summer sales of its yoghurts and plant-based products. Dozens of major French companies have emerged as first-time partners of the Olympic Games this year, hoping...
Comerica quarterly profit slumps on weaker interest income
Comerica quarterly profit slumps on weaker interest income
Apr 18, 2024
April 12 (Reuters) - U.S. lender Comerica ( CMA ) on Thursday reported a 57.4% fall in its quarterly profit as higher deposit costs hurt its interest income from customers. A high interest rate environment has made it costly for banks to retain deposits from customers who are increasingly seeking better returns in higher-yielding alternatives. Comerica's ( CMA ) net...
Revive Therapeutics Announced FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
Revive Therapeutics Announced FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
Apr 18, 2024
07:57 AM EDT, 04/18/2024 (MT Newswires) -- Revive Therapeutics ( RVVTF ) , a specialty life sciences company, on Thursday announced that the U.S. Food and Drug Administration has assigned it a meeting date of June 7. Revive had requested a meeting to discuss its Point of Care Lateral Flow Test Kit for feedback on strategy for the device that...
Cerevel's Parkinson's disease drug improves symptom control in late-stage trial
Cerevel's Parkinson's disease drug improves symptom control in late-stage trial
Apr 18, 2024
April 18 (Reuters) - Cerevel Therapeutics ( CERE ) said on Thursday its Parkinson's disease drug improved symptom control in patients when tested as an add-on therapy, meeting the main goal in a late-stage study. The trial, which enrolled 507 adults, tested Cerevel's tavapadon as an add-on therapy to levodopa, the standard of care for the nervous system disorder that...
Copyright 2023-2026 - www.financetom.com All Rights Reserved